Search Results
Jan 04, 2026, 04:30 ET 2026 年國際消費電子展 (CES 2026) 不容錯過的亮點
Default Male AI, presented by K'ept Health) 1 月 6 日上午 9 時 55 分，威尼斯人酒店 (The Venetian)，Marcello 4404 GLP-1 效應：女性塑造健康未來，由 PwC 主辦 (The GLP-1 Effect: Women Shaping the Future of Health, presented by PwC) 1 月 6 日上午 10 時 50 分，威尼斯人酒店 (The Venetian)，Marcello 4404
More news about: Consumer Technology Association
Jan 03, 2026, 15:50 ET Qué no perderse en CES 2026
masculina predeterminada, presentado por K'ept Health6 de enero, 9:55 AM, Venetian, Marcello 4404El efecto GLP-1: las mujeres que dan forma al futuro de la salud, presentado por PwC6 de enero, 10:50 AM, Venetian, Marcello 4404Apariciones
More news about: Consumer Technology Association
Jan 03, 2026, 15:33 ET CES 2026에서 놓쳐서는 안 되는 것들
4404여성 건강 기술의 혁신: AI의 남성 편향성 종식과 포용적 설계(케이엡트 헬스(K'ept Health) 발표)1월 6일 오전 9:55, 베네시안, 마르셀로 4404GLP-1 효과: 여성이 이끄는 헬스케어의 미래(PwC 발표)1월 6일 오전 10:50, 베네시안, 마르셀로 4404유명 인사 및 게스트 출연
More news about: Consumer Technology Association
Jan 03, 2026, 15:02 ET CE QU'IL NE FAUDRA PAS MANQUER AU CES 2026
à l'IA masculine par défaut, présenté par K'ept Health6 janvier, 9h55, Venetian, Marcello 4404L'effet GLP-1 : les femmes façonnent l'avenir de la santé, présenté par PwC 6 janvier, 10h50, Venetian, Marcello 4404Apparitions
More news about: Consumer Technology Association
Jan 03, 2026, 14:54 ET WAS SIE AUF DER CES 2026 NICHT VERPASSEN SOLLTEN
Women: Ending Default Male AI, presented by K'ept Health6. Januar, 9:55 Uhr, Venetian, Marcello 4404The GLP-1 Effect: Women Shaping the Future of Health, presented by PwC 6. Januar, 10:50 Uhr, Venetian, Marcello 4404Prominente
More news about: Consumer Technology Association
Jan 02, 2026, 16:50 ET Menu-Order-AI Launches on Google Play Store, Expanding Global Access to Its Real-Time GLP-1 Dining Companion
Menu-Order-AI, the real-time GLP-1 dining companion, announced today that it is now available on the
More news about: MENU - ORDER AI
Jan 02, 2026, 13:37 ET WHAT NOT TO MISS AT CES 2026
Women: Ending Default Male AI, presented by K'ept HealthJanuary 6, 9:55 AM, Venetian, Marcello 4404The GLP-1 Effect: Women Shaping the Future of Health, presented by PwC January 6, 10:50 AM, Venetian, Marcello 4404Celebrity
More news about: Consumer Technology Association
Jan 02, 2026, 13:10 ET WHAT NOT TO MISS AT CES 2026
Ending Default Male AI, presented by K'ept HealthJanuary 6, 9:55 AM, Venetian, Marcello 4404The GLP-1 Effect: Women Shaping the Future of Health, presented by PwC January 6, 10:50 AM, Venetian, Marcello 4404Celebrity
More news about: Consumer Technology Association
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
New Drug Application to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg), the first injectable GLP-1 receptor agonist and amylin analogue combination for weight management. In the REDEFINE 1 phase 3 trial, adults with obesity or overweight with
More news about: USA News Group
Dec 30, 2025, 18:13 ET Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
characterized by delayed gastric emptying and persistent nausea/vomiting, as well as for the prevention of nausea and vomiting induced by GLP-1 receptor agonists—a common side effect impacting adherence in the rapidly growing obesity and diabetes treatment landscape. Vanda anticipates
More news about: Vanda Pharmaceuticals Inc.
Dec 30, 2025, 14:02 ET 2026 Life Time Wellness Survey Results Are In: Strength Training and Longevity Lead New Year Priorities with 82% Focused More on Wellbeing
tracking.Looking ahead, respondents identified longevity (37.8%) as the wellness trend most likely to define 2026, followed by GLP-1 medications and peptides (24.4%) and AI-guided training (14.6%).Sleep tops snacks: Nearly 69% of respondents said they'd pick always
More news about: Life Time, Inc.
Dec 30, 2025, 13:54 ET Parker Waichman LLP Files Lawsuit on behalf of Philadelphia Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a
More news about: Parker Waichman LLP
Dec 29, 2025, 10:01 ET Maria Sharapova Teams up with Tempo to Bring Easy, Balanced Meals to Busy Pros
20%+ of the daily value of fiber, in addition to supporting gut health. These nutrient-dense meals are also formulated to be GLP-1 balanced, designed to support modern wellness lifestyles by delivering steady energy, satisfaction, and the nutrition needed to stay focused, active,
More news about: Home Chef
Dec 29, 2025, 08:31 ET MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Dec 26, 2025, 08:19 ET Baker Health Launches MELT, a Personalized, Capsule-Based Weight Loss Program Designed as a Non-Injection Alternative to GLP-1s
personalized, multi-month, capsule-based weight loss program designed for individuals seeking a medically supervised alternative to injectable GLP-1 medications. The program reflects a growing demand for effective oral weight-loss solutions that prioritize personalization, tolerability, and long-term
More news about: Baker Health
Dec 24, 2025, 23:05 ET 康霈減脂新藥CBL-514完成美國FDA體重管理適應症二期臨床IND申請 擴展與GLP-1類減重藥聯用之研發布局
EXA（雙能量X光吸收測定法）來收集體組成變化數據（包含體脂率、內臟脂肪與肌肉含量），為了降低偏差，MRI與DEXA將由第三方CRO進行盲性獨立數據判讀與分析後再進行後續統計。近年來 GLP-1R促效劑（GLP-1 receptor agonist 或 GLP-1R Agonist）類減重藥物快速普及，帶動全球體重管理市場顯著成長，國際關注亦逐步由體重大幅下降，轉向減少更多脂肪與停藥後體重維持、體組成改善、長期體重管理等健康減重議題。臨床顯
More news about: 康霈生技
Dec 24, 2025, 21:05 ET Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management field.
More news about: Caliway Biopharmaceuticals
Dec 23, 2025, 00:03 ET Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
exhaustion of CD8⁺ T cells and restored their functional capacity through localized activation, minimizing systemic exposure.In comprehensive GLP toxicology studies in cynomolgus monkeys, FP008 exhibited a favorable safety profile at doses up to 10 mg/kg, with no significant hematological adverse
More news about: Fapon Biopharma
Dec 22, 2025, 18:03 ET FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
Operations at Novo Nordisk. "Wegovy® pill is the next chapter in our decades-long GLP-1 experience—supported by the most affordable self-pay price to date in a GLP-1 for obesity. We are prepared for a full US launch in early January 2026, with manufacturing well underway
More news about: NOVO NORDISK INC.
Dec 22, 2025, 11:00 ET FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers
demonstrated:High medication adherence and persistenceClinically significant weight reduction leveraging both GLP-1s and non GLP-1sMeaningful improvements in LDL, HbA1c, and blood pressureSustained engagement driven
More news about: FlyteHealth
Dec 22, 2025, 10:11 ET 10 Days, 10 Ways to Spend FSA (Flexible Spending Account) Funds Before the December 31 Use-It-or-Lose-It Deadline, from FSA Store®
Daybreak Health; prescription GLP-1
More news about: Health-E Commerce
Dec 22, 2025, 08:31 ET MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Dec 22, 2025, 08:00 ET AI Platform to Combat Muscle Loss and Preserve Metabolic Vitality for GLP-1 Users
circadian rhythms and somatic balance—to help GLP-1 users stay engaged in supportive nutrition, movement, and daily routines while working toward long-term health goals.More than 37 million Americans currently use GLP-1 agonists such as Wegovy and Zepbound. Public health
More news about: Livelively USA Inc
Dec 21, 2025, 20:00 ET 復星國際榮獲TVB頒發最高級別的「ESG年度卓越大獎」
復星醫藥已上市的CAR-T細胞治療產品奕凱達®（阿基侖賽注射液）位列其中。這些創新藥在醫保談判中的成功，不僅體現了國家對醫藥創新的支持，也為這些藥物的市場推廣和患者使用提供了有力保障。復星的創新實力同樣獲得國際藥企的高度認可。12月9日，復星醫藥宣佈其控股子公司與輝瑞簽署許可協議，將口服小分子胰高血糖素樣肽‑1（GLP‑1）受體激動劑（包括 YP05002）及含有該活性成分的產品授予輝瑞於全球範圍及領域獨家開發、使用、生產及商業化權利。與此同時，復星積極整合全球資源，加速前沿醫療科技在中國落地，提升醫療技術的可及性與普惠性。截至2025年9月底
More news about: 復星
Dec 21, 2025, 20:00 ET Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient.At the same time, Fosun actively integrates global resources
More news about: Fosun